Patents Assigned to Merck Sharp & Dohme LLC
  • Publication number: 20260345736
    Abstract: The use of a long-acting oxyntomodulin derivative for treatment of fatty liver disease is disclosed. In particular, disclosed is the use of efinopegdutide and pharmaceutically acceptable salts thereof for treating nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
    Type: Application
    Filed: June 18, 2024
    Publication date: November 5, 2026
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Eirum CHAUDHRI, Samuel ENGEL, Keith D. KAUFMAN
  • Publication number: 20260345719
    Abstract: Disclosed are compositions, including pharmaceutical compositions, comprising a combination of sitagliptin, or a pharmaceutically acceptable salt and/or hydrate thereof, and an antioxidant.
    Type: Application
    Filed: October 19, 2023
    Publication date: November 5, 2026
    Applicant: Merck Sharp & Dohme LLC
    Inventors: MARCO EUCLIDE ARMENANTE, MATTHEW KYLE BURRIS, ROBERT CLARK, MICHAEL B. GENTZLER, ANDREW J. GMITTER, EVANGELIA SPARTALIS, JINJIAN ZHENG
  • Patent number: 12782372
    Abstract: A GUI is used to schedule a set of tasks for one or more robots to test samples using one or more instruments. A set of drivers are used to map instructions for the robots and instruments form a standardized format to a set of instrument/robot-specific formats. Using the standardized formats enables support for new types of robot and/or instrument to be easily added to the system. The robots and instruments generate test results from samples according to the instructions. Information about the testing may be stored in conjunction with user identifiers and other metadata to provide a verifiable audit trail across the instruments and robots.
    Type: Grant
    Filed: October 20, 2023
    Date of Patent: November 3, 2026
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Edward M. Hudak, Jason A. Cassaday, Brian Andrew Squadroni
  • Patent number: 12773391
    Abstract: The present disclosure provides, among other things, lipid nanoparticle formulations that include monoester cationic lipids. The present invention also provides compositions that include monoester cationic lipid nanoparticles and nucleic acids. The present disclosure also provides lipid nanoparticles encapsulating agents. The present disclosure further provides methods of producing lipid nanoparticles with encapsulated nucleic acids.
    Type: Grant
    Filed: December 1, 2021
    Date of Patent: October 27, 2026
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Marian E. Gindy, Andrew Bett, Izzat Tiedje Raheem, Ronald M. Kim
  • Patent number: 12773448
    Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and/or pneumococcal diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.
    Type: Grant
    Filed: August 2, 2024
    Date of Patent: October 27, 2026
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Chitrananda Abeygunawardana, Yadong Adam Cui, Romulo Ferrero, Jian He, Luwy Musey, Tanaz Petigara, Julie M. Skinner
  • Publication number: 20260327312
    Abstract: The invention relates to compositions and methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody (e.g. pembrolizumab), or antigen binding fragment thereof, with or without hyaluronidase every six weeks, in specific amounts to the patient. In specific embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 600 mg to about 1000 mg. In specific embodiments, the administration occurs about every three weeks, and the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 300 mg to about 500 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a particular dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.
    Type: Application
    Filed: February 9, 2026
    Publication date: October 22, 2026
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Omobolaji O. Akala, Carolina De Miranda Silva, Elliot Keith Chartash, Mallika Lala, III, Kapil Mayawala
  • Publication number: 20260325629
    Abstract: Backgrounds: The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to expand pneumococcal disease protection. This phase 3 study evaluated key safety and immunogenicity data of PCV20 with a 4-dose infant immunization series. Methods: In this phase 3, double-blind study (NCT04382326) conducted in the United States and Puerto Rico, healthy infants were randomized equally to receive 4 doses of PCV20 or PCV13 at 2, 4, 6, and 12-15 months of age. Objectives included noninferiority of immunoglobulin G (IgG) geometric mean concentrations (GMCs; 2-fold criterion) at 1 month after Dose 4 (co-primary) and Dose 3 (key secondary), and participants (%) with predefined IgG concentrations 1 month after Dose 3 (co-primary; 10% criterion). The 7 additional PCV20 serotypes were compared with the lowest result among vaccine serotypes in the PCV13 group for noninferiority evaluation. Other objectives included demonstration of opsonophagocytic activity (OPA) and boosting responses.
    Type: Application
    Filed: May 16, 2024
    Publication date: October 22, 2026
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Patrick L. AHL, Peter J. MANLEY, Izzat T. RAHEEM, W. Michael SEGANISH, William J. SMITH
  • Patent number: 12760005
    Abstract: I: wherein is wherein n is 0 or 1; The present invention is directed to bicyclo[4.1 0]heptane pyrrolidine compounds of formula (I) which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: October 13, 2026
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Stephane L. Bogen, Dane James Clausen, Deodial Guy Guiadeen, Jinsong Hao, Shishi Lin, Michael T. Rudd, Lan Wei, Li Xiao, Dexi Yang
  • Patent number: 12760037
    Abstract: The present invention provides a compound of formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Grant
    Filed: March 16, 2022
    Date of Patent: October 13, 2026
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Natalija Cernaka, Anthony K. Ogawa, Alan C. Cheng, Jianming Bao, Phillip Patrick Sharp, Jovan Alexander Lopez, Dong Xiao, Haiqun Tang
  • Patent number: 12760026
    Abstract: The present invention is directed to certain (hetero)aroyl 4-aminopyrazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: October 13, 2026
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Kaleen Konrad Childers, J. Michael Ellis, Peter J. Fuller, Hakan Gunaydin, Jack D. Scott, Haiqun Tang, Charles S. Yeung
  • Publication number: 20260306649
    Abstract: Provided herein are methods for treating cancers with antibody drug conjugates (ADC) that bind to 191P4D12 protein (Nectin-4) and pembrolizumab.
    Type: Application
    Filed: July 24, 2023
    Publication date: October 8, 2026
    Applicants: AGENSYS, INC., SEAGEN INC., MERCK SHARP & DOHME LLC
    Inventors: Anne-Sophie CARRET, Oyewale O. ABIDOYE
  • Publication number: 20260306652
    Abstract: Anti-TROP2 antibody-drug conjugates comprising derivatives of the anthracycline metabolite PNU-159682 conjugated to an antibody that preferentially binds high-expressing TROP2 cells over low-expressing TROP2 cells are disclosed.
    Type: Application
    Filed: April 19, 2024
    Publication date: October 8, 2026
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Minilik ANGAGAW, Edward Paul BOWMAN, Ming-Tang CHEN, Laurence FAYADAT-DILMAN, Malgorzata A. GIL, Marlene C. HINTON, Zhong HUA, Rebecca Elizabeth JOHNSON, Simon B. LANG, W. Michael SEGANISH, Andrew B. WAIGHT
  • Publication number: 20260308203
    Abstract: Peptidomimetic macrocycles that comprise all-D configuration ?-amino acids and bind mouse double minute 2 (MDM2 aka E3 ubiquitin-protein ligase) and MDMX (aka MDM4) are described. These all-D configuration ?-amino acid peptidomimetic macrocycles are protease resistant, cell permeable without inducing membrane disruption, and intracellularly activate p53 by binding MDM2 and MDMX thereby antagonizing MDM2 and MDMX binding to p53. These peptidomimetic macrocycles may be useful in anticancer therapies, particularly in combination with chemotherapy or radiation therapy.
    Type: Application
    Filed: June 9, 2026
    Publication date: October 8, 2026
    Applicants: Merck Sharp & Dohme LLC, Agency for Science, Technology and Research, MSD International GMBH (Singapore Branch)
    Inventors: Pietro Aronica, Christopher J. Brown, Fernando J. Ferrer, Charles W. Johannes, Srinivasaraghavan Kannan, David P. Lane, Anthony W. Partridge, Tomi K. Sawyer, Yaw Sing Tan, Chandra S. Verma, Tsz Ying Yuen
  • Patent number: 12753163
    Abstract: Compounds of the formula I: or the pharmaceutically acceptable salts thereof, are inhibitors of haematopoietic progenitor kinase 1 (HPK1) useful in the treatment of diseases or disorders associated with HPK1. Also disclosed herein are uses of these compounds in the potential treatment or prevention of an HPK1-associated disease or disorder. Also disclosed herein are compositions comprising one or more of the compounds. Further disclosed herein are uses of these compositions in the potential prevention or treatment of an HPK1-associated disease or disorder.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: October 6, 2026
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Abdelghani Achab, David A. Candito, Anthony Donofrio, Xavier Fradera, Shuhei Kawamura, Samuel M. Levi, Bing Li, Anilkumar G. Nair, Alexander Pasternak, Brandon A. Vara, Elsie C. Yu
  • Patent number: 12753187
    Abstract: The present invention relates to novel Amido-Substituted Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: October 6, 2026
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Richard Thaddeus Berger, Jr., Christopher Douglas Cox, Brendan M. Crowley, Marc Labroli, Michael Aaron Plotkin, Izzat Tiedje Raheem, Deyou Sha, Anthony W. Shaw, Jason W. Skudlarek, Ling Tong
  • Patent number: 12753190
    Abstract: Described herein are compounds of Formula I; and pharmaceutically acceptable salts thereof, wherein A, X, R1, R2, m, n, and p are as defined herein. The compounds of Formula I, and pharmaceutically acceptable salts thereof, act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Grant
    Filed: October 24, 2022
    Date of Patent: October 6, 2026
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Abdelghani Abe Achab, Jenny Lorena Rico Duque, Xavier Fradera, Joey L. Methot, Phieng Siliphaivanh, Brandon A Vara, Hongjun Zhang
  • Publication number: 20260297134
    Abstract: Disclosed are cyclic peptides, their salts, pharmaceutical compositions comprising them, diagnostic and therapeutic uses and processes for making such compounds, which bind to granzyme B and may be suitable for imaging granzyme B. Further provided are compounds useful as a radiotracer for positron emission tomography (PET) and/or single photon emission tomography (SPECT) imaging. The use of the compounds as imaging agents of granzyme B is further disclosed.
    Type: Application
    Filed: April 29, 2024
    Publication date: October 1, 2026
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Idriss Bennacef, Tapan K. Nayak, Jeffrey William Schubert, William D. Shipe, David M. Tellers, Federica Orvieto, Valerio Piacenti
  • Patent number: 12747244
    Abstract: The present invention relates to efficient synthetic processes useful in the preparation of Compound A, a BTK inhibitor of Formula (I): or a pharmaceutically acceptable salt thereof, including the preparation of intermediates used to make Compound A or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 26, 2022
    Date of Patent: September 29, 2026
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Yonggang Chen, James Corry, Richard Desmond, Michael J. Di Maso, Jacob H. Forstater, Jeffrey T. Kuethe, Nadine Kuhl, Reed Larson, Francois Levesque, Karthik Narsimhan, Douglas Otte, Christopher K. Prier, Michael Shevlin, Eric Sirota, Lushi Tan, David A. Thaisrivongs, Ben W. H. Turnbull, Zhixun Wang, Kaijiong Xiao
  • Publication number: 20260274956
    Abstract: Provided herein are methods of separating host cell proteins from anti-PD-1 antibodies or antigen binding fragments in chromatographic processes.
    Type: Application
    Filed: May 12, 2026
    Publication date: September 17, 2026
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Mark A. BROWER, Nuno Jorge DOS SANTOS PINTO, William J. RAYFIELD, Julie R. ROBINSON
  • Patent number: 12735425
    Abstract: The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W1, W2, Y, Z, CA, R1, R2a, and R2b are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: September 15, 2026
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Yongxin Han, Elisabeth Hennessy, Andrew J. Hoover, Jesus Moreno, Uma Swaminathan